The Ibuprofen TEPI Patch is the most advanced product in Medherant's portfolio:
- Non-clinical safety studies have been completed - no concerns were raised by any of the studies
- Two Phase I studies were completed in 2018
- Irritation and sensitisation
- Pharmacokinetics versus oral ibuprofen
A Phase III efficacy study is required to complete the clinical programme for EU registration. The study design has been agreed with regulatory agencies.
Medherant is seeking partners to complete the development programme and commercialise the product.
* AlliedMarketResearch report (2018)